Two abstracts accepted for oral presentation at the 13th London International Cough Symposium Leerink Partners Therapeutics Forum: I&I and Metabolism
July 9-10, 2024, Boston, MA
Trevi Representatives: Jennifer Good, President and CEO, and Lisa Delfini, CFO
The Thirteenth London International Cough Symposium July 18-19, 2024, London, UK
Symposium Focus: The Thirteenth London International Cough Symposium brings together clinicians, scientists, and researchers in the field of cough from across the world. The purpose of this symposium is to share, review and discuss emerging ideas, novel approaches, and clinical research advancements in the management of chronic cough. Oppenheimer's Biotech in the Berkshires
August 5-7, 2024, Lenox, MA
Trevi Representative: Jennifer Good, President and CEO
August 12-14, 2024, Newport RI
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, CCO
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US. Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.